Live reduced-toxicity chickenpox vaccine has been proven to be an effective and sustainable disease prevention measure; in which, the MAV/06 strain is increasingly being concerned thanks to its safety and stable immune-generating ability.
In medical practice, whether a child who has had chickenpox needs to be vaccinated or not is always a question raised by doctors.
To answer, it is necessary to clarify the difference between post-infection immunity and immunity created by vaccines.
After contracting chickenpox, most children have immunity to Varicella zoster virus (VZV), but the level is uneven and depends on the severity of the disease, age of onset and health condition.
Children with very mild illnesses or at too young ages can develop low, unsustainable immune responses; in addition, some cases are misdiagnosed, so they are not sure about their medical history [1].
Many studies record the risk of chickenpox recurrence when immunity is weakened, especially in children who have had mild diseases with low levels of antibodies.
The US CDC also affirmed that the VZV virus potentially exists in the nerve ganglia and can reactivate when immunity is weakened, causing zona [1].
Chickenpox vaccine at this time will act as an immune-strengthening tool. The MAV/06 live reduced virulence chickenpox vaccine is developed to stimulate effective immune response.
Preclinical and clinical data show that MAV/06 creates a strong response to VZV-resistant IgG antibodies, while activating cell immunity - a key factor in controlling latent viruses. The disease prevention effectiveness is about 80-90% for all levels of chickenpox and over 95% for severe chickenpox [2,3,4].
According to WHO and the US CDC, chickenpox vaccination for children who have had the disease is safe. Post-vaccination reactions are mainly mild and transient, not recording the risk of virus reactivation or causing zona or any serious adverse reactions [3,4].
WHO and CDC recommend chickenpox vaccination in cases of unclear medical history, very mild illness, too young age or when long-term protection is needed [5].
The MAV/06 – Barycela chickenpox vaccine acts as an effective and safe immune booster, contributing to protecting children's health for a long time.
BARYCELA Inj., a new generation chickenpox vaccine developed by GC Biopharma from MAV/06, achieves immune efficacy and safety equivalent to Oka vaccine, and can be used in the current two-dose injection schedule [10].
Recommended 2-dose vaccination schedule to create optimal immunity
12 months – 12 years old:
- Nose 1: from 12 months old
- Dose 2: at least 3 months after dose 1 or booster shot when children are 4–6 years old.
In Vietnam, NAVIVA GROUP is a unit authorized to distribute the MAV/ 06 generation 2 chickenpox vaccine called BARYCELA inj. (GC Biopharma - Korea). With more than 21 years of experience in the field of vaccines and medical biologicals, NAVIVA GROUP cooperates with medical facilities to enhance access to safe - effective - quality vaccines for the community.
The unit commits to ensuring stable supply, strictly complying with the preservation - transportation process according to GSP/GDP standards; and accompanying activities to raise awareness about proactive and safe vaccination.
💭Hotline for consultation: 0905 584 666
Facebook Website: www. naviva. com. vn
Facebook Email: info@naviva. com. vn
References
Centers for Disease Control and Prevention (CDC)– Chickenpox Vaccine Recommendations: https://www. cdc. gov/chickenpox/hcp/vaccine-considerations/index. html
CDC – About the Varicella Vaccine: https://www. cdc. gov/vaccines/vpd/varicella/hcp/about-vaccine. html
World Health Organization (WHO). Varicella and herpes zoster vaccines: WHO position paper – November 21, 2025: https://www. who. int/publications/i/item/who-wer10047-567-590
Hong K et al. Effectiveness of two-dose varicella vaccination: Bayesian network meta-analysis. Pediatr Infect Vaccine. 2024;31(1):55–63.
CDC – Chickenpox (Varicella) Vaccine Safety: https://www. cdc. gov/vaccine-safety/vaccines/varicella. html
